Persomics Granted Patents Protecting Phenotypic Screening Technology in Europe and South Africa

Share Article

Persomics AB, a leading biotechnology company with innovative solutions that miniaturize, accelerate and increase the scale of phenotypic screening, has been granted patents on a proprietary miniaturized screening technology in Europe and South Africa.*

“Persomics is building a strong portfolio of intellectual property around its core technology. It is fantastic news that patents for our technology have been granted in Europe and South Africa”, says Neil Emans Ph.D., the inventor of Persomics technology and CEO of Persomics USA Inc. “The European patent was granted within 3 years of filing, which is an indication of the novelty of our core technology and the strength of our intellectual property. Our ambition is to continue to innovate and bring new solutions to the market in 2015.” 

Persomics recently announced their ImagineArraysTM at the 2015 High-Content Analysis conference in San Diego and at the 2015 SLAS meeting in Washington DC.

“We are excited to have been granted patents in key markets for Persomics’ miniaturization technology,” says Martin Svensson, CEO of Persomics AB. “We have strong interest from pharmaceutical, biotech and academic organizations, that understand how Persomics’ enabling technology will support advances in drug discovery, functional genomics and phenotypic screening.”

The growing suite of intellectual property and in-licensed capabilities provides Persomics with a unique and defensible position in providing miniaturized functional genomics screening tools for research and drug discovery.

*European Patent No. 2736631 and South African Patent No. 2014/01389

About Persomics
Persomics provides ImagineArraysTM, a technology that miniaturizes, accelerates and increases the scale of RNAi in phenotypic screening. Researchers investigating the function of the human genome are no longer limited by automation requirements or cost, but just by their need to discover more. With Persomics this can be achieved at a fraction of the investment required in large industrial research labs. With our technology the science can go further, faster. For more information, please visit

Please send enquiries to:
Sean Moolman, Ph.D.
IP Manager

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mike Sjaastad
+1 (650) 678-9097
Email >
Visit website